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Edited by Barry HalliwellAbstract Cannabinoid ligands are implicated in many physio-
logical processes and to date two receptors have been identiﬁed.
However, a growing body of evidence exists that suggests the
presence of additional receptors. Whilst cloning the previously
described hCB1a, we have identiﬁed a novel variant that we call
hCB1b. Characterising these two splice variants demonstrates
that they have a unique pharmacological proﬁle and that their
RNA’s are expressed at low levels in a variety of tissues.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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To date two cannabinoid receptors have been described in
man, the hCB1 receptor [1] and the hCB2 receptor [2]. Expres-
sion of the CB1 receptor was initially described in brain and is
considered essentially as a central nervous system (CNS) recep-
tor [1,3,4] where an intricate CB1 receptor network is exercis-
ing a range of activities pre- as well as post-synaptically. These
activities can drive or modulate other neurotransmitter signal-
ling cascades and may thus originate even at the level of indi-
vidual neurons. This ‘‘switch-board’’ functionality has
implications for interpreting the presence of very low levels
of receptors at discreet CNS sites with a distinct pharmacol-
ogy. More recently, the CB1 receptor has also been found in
a number of peripheral tissues such as the cardiovascular sys-
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doi:10.1016/j.febslet.2004.11.085hCB2 receptor, with 44% homology to hCB1 receptor, appears
to be associated predominantly with the immune system [2].
Cannabinoid receptors are activated by D9-THC, the psy-
choactive component of Cannabis sativa, leading to analgesia,
inhibition of nausea, lowering of intraocular pressure, appetite
stimulation, antiemetic activity and bronchial dilation [9].
Endogenous ligands to these receptors include arachidonoyle-
thanolamide (anandamide) [10], 2-arachidonoylglycerol (2-
AG) [11] and 2-arachidonoyl ether (noladin ether) [12], the
latter having a high aﬃnity for CB1 receptors but binding only
weakly to CB2. These endocannabinoids can cause various de-
grees of sedation, hypothermia, altered intestinal immobility
and mild antinociception in mice, suggesting that they function
at CB1 receptors in vivo [12]. Recently, a fourth endocannabi-
noid was identiﬁed, o-arachidonoylethanolamine (virodh-
amine). Virodhamine is a partial agonist at the hCB1
receptor and acts as a full agonist at hCB2 [13]. In addition,
a number of endocannabinoid-like molecules have been de-
scribed that lack activity on CB1 or CB2 receptors. There is
also a broad range of synthetic cannabinoid ligands with dis-
tinct functions at CB1 and CB2 receptors. These include the
agonists CP55940, WIN55,212-2, and HU-210 and the antag-
onists SR141716, AM251 (both CB1 selective) and AM630
(CB2 selective) [14].
The existence of hCB1a, an amino terminal splice variant of
the hCB1 receptor, has previously been described [15]. It was
during the process of cloning this receptor that we identiﬁed
a new variant we have called hCB1b. Both splice variants have
altered ligand binding and activation properties as compared
to the full-length hCB1 receptor and are expressed at very
low levels in a variety of tissues.2. Materials and methods
2.1. PCR, cloning and sequence analysis of hCB1b
The novel hCB1b variant was identiﬁed and cloned by polymerase
chain reaction (PCR) using the protocol described by Shire et al.
[15]. The forward hCB1-F (5 0-TATGAAGTCGATCCTAGATGG-
3 0) and reverse primers hCB1-3R (5 0-GTTCTCCCCACACTG-
GATG-3 0) were used in a PCR mixture of 50 ll, containing 2 ll of a
pre-made human foetal brain cDNA library in pcDNA3.1+ (Invitro-
gen, cat A550-24), 1· PCR buﬀer (10 mM Tris–HCl, pH 9.0, 1.5
mMMgCl2, and 50 mMKCl), 0.4 mM dNTPs (Amersham–Pharmacia
Biotech), 5 U Taq polymerase (Amersham–Pharmacia Biotech) and 50
pmol of each hCB1-F and hCB1-3R primers. The resulting product
was resolved on a 1% agarose gel and only a major band at 304 bpblished by Elsevier B.V. All rights reserved.
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The 0.1–0.25 Kb gel area was excised and puriﬁed with QIAquick
gel extraction kit (Qiagen). A second round of PCR was performed
on the puriﬁed material and the resulting product was resolved on a
1% agarose gel. A major band at 205 bp was isolated before sub clon-
ing into pGEMT Easy Vector (Promega). The plasmids were se-
quenced using an ABI Prism dRhodamine cycle sequencing ready
reaction kit (Perkin Elmer Applied Biosystems).
The whole coding region of the human CB1b receptor was ampliﬁed
using the same conditions and template as described above with the
following forward and reverse primers (5 0-TATGAAGT-
CGATCCTAGATGG-3 0 and 5 0-AATTCTTTTCCTGTGCTGCC-
3 0). The resulting product was resolved on a 1% agarose gel and the
band of approximately 1300 bp was puriﬁed using QIAquick gel
extraction kit before subcloning into pGEMT Easy Vector and se-
quenced (GenBank Accession No. AY766182).
For functional characterisation, the hCB1b cDNA was introduced
in the HindIII and XbaI restriction sites of the pcDNA3 expression
vector (Invitrogen).
2.2. Cell transfection and membrane preparation
5 · 106 HEK293s cells were seeded in T75 ﬂasks and after 24 h cells
were transiently transfected with 10 lg of relevant plasmid using Lipo-
fectamine Plus (Invitrogen). Membranes were prepared after 48 h
using standard methods and stored at 80 C. Protein concentra-
tion was measured according to the method of Bradford (Bio-Rad
Laboratories).
2.3. [3H-CP55940]Ligand binding
Radioligand binding was initiated by the addition of 5 lg of mem-
brane protein to each well of a 96-well plate containing 1.5 nM
[3H]CP55940 (Amersham–Pharmacia Biotech) (>90% of radioligand
remained unbound), the required concentration of competitor ligand
and a suﬃcient volume of buﬀer (50 mM Tris–HCl, 5 mM MgCl2,Fig. 1. Sequence of the hCB1b receptor. Sequence alignment of hCB1, hC
terminus. The misalignment of the hCB1a amino terminal region represents50 mMNaCl, pH 7.4, and 0.1% BSA) to bring the total volume of each
well to 200 ll. Non-speciﬁc binding was determined in the presence of
2 lM CP55940 (Tocris) and total binding in the absence of any com-
petitior. The membranes were incubated at 30 C for 90 min and the
reaction was then terminated by addition of ice-cold wash buﬀer (50
mM Tris–HCl, 5 mM MgCl2, and 50 mM NaCl, pH 7.4) followed
by rapid ﬁltration under vacuum through Printed Filtermat A glass ﬁ-
ber ﬁlters (Wallac) [0.05% polyethylenimine (PEI) treated] using a Mi-
cro 96 Harvester (Skatron Instruments). The ﬁlters were dried for 30
min at 50 C, then a paraﬃn scintillant pad was melted onto the ﬁlters
and the bound radioactivity was determined using a 1450 Microbeta
Trilux (Wallac) scintillation counter and the data ﬁtted using the equa-
tion y = A + ((B  A)/1 + ((C/x)D))) and the IC50 estimated where A
is the non-speciﬁc binding, B is the total binding, C is the IC50 and D is
the slope. The ligands used were obtained from Tocris.
2.4. [35S]GTPcS binding assay
[35S]GTPcS binding assays were performed at 30 C for 45 min in
membrane buﬀer (100 mM NaCl, 5 mM, 1 mM EDTA, and 50 mM
HEPES, pH 7.4) containing 0.025 lg/ll of membrane protein with
0.01% bovine serum albumin (fatty acid free), 10 lM GDP, 100 lM
DTT and 0.53 nM [35S]GTPcS (Amersham-Pharmacia Biotech) in a ﬁ-
nal volume of 200 ll. Non-speciﬁc binding was determined in the pres-
ence of 20 lM guanosine 5 0-[c-35S]-triphosphate (GTPcS). The
reaction was terminated by addition of ice-cold wash buﬀer (50 mM
Tris–HCl, 5 mM MgCl2, and 50 mM NaCl, pH 7.4) followed by rapid
ﬁltration as described above. Data were ﬁtted as described above.
2.5. Tissue distribution
Tissue distribution of hCB1a and hCB1b was performed using PCR
on tissue-derived cDNAs (Gene PoolTM cDNAs; Invitrogen). 25 pmol
each of the following forward hCB1-splice-F (5 0-CCTAATCAAA-
GACTGAGGTTATGAAGTC-3 0) and reverse hCB1-splice-R (5 0-
AGTTCTCCCCACACTGGATGTT-3 0) primers was used in a PCRB1a and hCB1b demonstrating the diﬀerences in the receptors amino
the frame shift that is used to generate that sequence.
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PCR Master Mix (ABgene). Ampliﬁcation was carried out in a PTC-
200 (MJ Research) for 35 cycles; 94 C for 30 s, 57 C for 45 s and
72 C for 1 min. The resulting products were resolved on 3% agarose
gels and a major band at 324 bp corresponding to the human un-
spliced CB1 receptor was detected. The 0.12–0.25kb gel area was ex-
cised and melted (at 95 C for 5 min) and used as template for further
PCR ampliﬁcation. This second round of PCR was performed using
the same conditions as described above with 4 ll of the melted material
as template. The resulting PCR product was again resolved on a 3%
agarose gel.3. Results
3.1. Identiﬁcation of hCB1b as a novel hCB1 splice variant
PCR products generated by the use of primers designed to
detect the hCB1a splice variant on a human foetal brain cDNA
library only identiﬁed a band equivalent to the 304 bp frag-
ment expected for the full-length hCB1 receptor. As described
under Section 2, a second round of PCR ampliﬁcation gener-
ated two bands of approximately 140 and 200 bp. The smaller
band is equivalent to the 137 bp band expected for the previ-
ously described hCB1a receptor splice variant. The larger band
represented a 205 bp fragment that upon sequencing was
shown to correspond to the 5 0 region of the hCB1 receptor.
To determine whether the alternative 5 0 cDNA sequence repre-
sented a full-length alternative splice form, primers were de-
signed to isolate the complete coding sequence of the
variant. A band of 1300 bp was identiﬁed and sequencing
showed that the alternative 5 0 sequence previously identiﬁed
is associated with a full-length cDNA that constitutes an
hCB1 receptor with an altered amino terminal sequence dis-
tinct from hCB1 and hCB1a that we have called CB1b (Fig.
1). Examination of the splice donor/acceptor sites in hCB1
gene sequence used to generate the hCB1b demonstrates the
use of classical splice donor/acceptor sequences. These splice
donor/acceptor sites are not conserved in the rodent CB1 genes
and we were unable to detect a rodent equivalent to hCB1b.
3.2. Functional characterisation of the human CB1b splice
variant
Following transient transfection into HEK293 cells, [3H]-
CP55940 radioligand binding was used to determine the aﬃn-
ity of various cannabinoid ligands for hCB1 and its two spliceTable 1
Competition binding activity of endogenous and synthetic cannabinoid
ligands at hCB1 receptor and its two splice variants expressed in
HEK293s cells using [3H]-CP55940 as radioligand
Ligand IC50 (nM)
hCB1 hCB1a hCB1b
Anandamide 50 ± 4.2 10967 ± 921 12467 ± 1604
2-Arachidonoylglycerol 227 ± 40 394 ± 17 697 ± 79
Noladin ether 21 ± 2 NE NE
Virodhamine 32700 ± 8237 NE NE
Palmitoylethanolamide NE NE NE
Oleylethanolamide NE NE NE
D9-THC 6.5 ± 0.6 9.7 ± 0.2 3.1 ± 0.5
CP55940 5.2 ± 0.6 5.0 ± 0.3 1.8 ± 0.2
WIN55-212,2 28 ± 7 2.9 ± 0.8 4.7 ± 0.4
HU210 0.30 ± 0.06 0.70 ± 0.15 0.33 ± 0.09
SR141716 6.7 ± 1.5 1.8 ± 0.5 4.7 ± 0.8
NE: no eﬀect of ligand in the assay up to 33 lM.
All data represent means ± S.E.M., where n = 5.variants (Table 1). There are four endogenous ligands
(anandamide, 2-AG, noladin ether and virodhamine) that have
been reported having an activity at hCB1 receptors [10–13]. In
addition, two related molecules palmitoylethanolamide (PEA)
and oleoylethanolamide (OEA) are reported to have no signif-
icant activity at the CB1 receptor [16,17]. We found that both
splice variants displayed a signiﬁcantly altered ability to bind
each of these cannabinoids (see Table 1) with only 2-AG able
to demonstrate signiﬁcant aﬃnity for the two splice variants.
In contrast, all synthetic ligands tested (D9-THC, CP55940,
SR141716 and HU210) displayed similar abilities to compete
for [3H]-CP55940 binding to CB1 and both splice variants
(Table 1).
We then examined the functional activity of these ligands.
Similar to its signiﬁcant loss of aﬃnity towards the splice vari-
ants, anandamide was less able to activate hCB1a and hCB1b
(Fig. 2). Consistent with the ﬁndings from competition binding
noladin ether, virodhamine, PEA and OEA had no eﬀect on
GTPcS binding mediated by either splice variant (Table 2).
In contrast, 2-AG was active but rather than behaving as an
agonist it functioned as an inverse agonist with IC50s of 287
nM (Fig. 2(b)) and 505 nM (Fig. 2(c)) at hCB1a and hCB1b,
respectively.
With respect to the activity of the non-endocannabinoid li-
gands, in the same way that a small increase in aﬃnity of
WIN55,212-2 was observed for each of the splice variants
an increased potency was also found, producing EC50s of
4.4 and 0.63 nM at hCB1a and hCB1b, respectively, com-
pared to 23 nM at hCB1 (Table 2). HU210, one of the most
potent ligands known to function at CB1, appeared not to
diﬀerentiate between the splice variants and hCB1 in the
binding assay. However, in the GTPcS assay the potency
was 31- and 15-fold reduced at hCB1a and hCB1b, respec-
tively (Table 2).3.3. Expression analysis of hCB1 splice variants
We next examined the tissue distribution using a quantitive
RT-PCR approach on various human tissue derived cDNAs.
Primers were designed that would produce products of 324,
157 and 225 bp for hCB1, hCB1a and hCB1b, respectively
(Fig. 3(a)). Consistent with the known tissue distribution,
hCB1 was readily detected in adult and foetal brain. InTable 2
GTPcS activity of endogenous and synthetic cannabinoid ligands at
hCB1 receptor and its two splice variants expressed in HEK293s cells
Ligand EC50 (nM)
hCB1 hCB1a hCB1b
Anandamide 28.7 ± 4.4 10270 ± 240 11017 ± 300
2-Arachidonoylglycerol 170 ± 29 287 ± 16a 505 ± 53a
Noladin Ether 5.97 ± 0.44 NE NE
Virodhamine 793 ± 110 NE NE
Palmitoylethanolamide NE NE NE
Oleylethanolamide NE NE NE
D9-THC 4.23 ± 0.24 4.13 ± 0.69 3.33 ± 0.32
CP55940 0.56 ± 0.16 1.4 ± 0.15 0.79 ± 0.13
WIN55-212,2 23 ± 0.58 4.4 ± 0.79 0.63 ± 0.07
HU210 0.05 ± 0.003 1.58 ± 0.27 0.77 ± 0.09
SR141716 1.93 ± 0.38a 6.8 ± 0.75a 3.2 ± 0.15a
NE: no eﬀect of ligand in the assay up to 33 lM.
All data represent means ± S.E.M., where n = 5.
aCompounds behave as inverse agonists.
Fig. 2. Eﬀect of cannabinoid ligands on GTPcS binding in membranes prepared from HEK293s cells expressing hCB1, hCB1a and hCB1b receptors.
D9-THC (+), anandamide (s), 2-AG ($) and SR141716 (D) were tested at a range of concentrations for their ability to elicit speciﬁc GTPcS binding
in membranes derived from HEK293s cells expressing (a) hCB1, (b) hCB1a and (c) hCB1b.
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els in heart, liver and kidney appeared to be extremely low
(Fig. 3(b)). The expected product derived from the hCB1a
was not detected in any tissue during a ﬁrst round of PCR.However, in foetal brain the hCB1b was detected though at
a low level (Fig. 3(b)). It should be noted, however, that this
level is equivalent to the hCB1 detected in peripheral tissues
such as spleen, uterus and muscle.
Fig. 3. Detection of hCB1, hCB1a and hCB1b in human tissue derived cDNA libraries. (a) Schematic representation of the rational for detecting
PCR products expected for the hCB1 (324bp), hCB1a (157bp) and hCB1b (225bp) transcripts. (b) Detection of various PCR products from ﬁrst
round (upper picture) and second round (lower picture) of hCB1, hCB1a and hCB1b receptors. The area excised after the ﬁrst round of PCR in order
to initiate the second round is indicated. The major band from the ﬁrst round represents the hCB1 receptor. The two principle bands detected in the
second round represent the hCB1a and hCB1b receptors.
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tected in other tissues, albeit at a very low level, the region be-
tween 125 and 250 bp was excised from the gel and the DNA
contained therein extracted in order to perform a second
round of PCR. Upon analysis of the resulting PCR products,
the hCB1a was detected in all tissues apart from liver and
spleen. It is not possible using such an approach to make a di-
rect comparison between the expression levels of hCB1 and
hCB1a but it is noteworthy that the levels of hCB1a vary inde-
pendently of the levels of hCB1 detected in each of the tissues.
The hCB1b displays a distribution pattern that is distinct from
that of hCB1a. Consistent with the observations from the ﬁrst
round of Q-PCR, the highest levels of hCB1b were detected in
foetal brain. hCB1b was not detected in skin, heart and liver
but was found to various extents in the other tissues tested.4. Discussion
Herein, we describe the identiﬁcation and characterisation of
a novel splice variant of the hCB1 receptor. The hCB1b is gen-erated by the use of splice donor/acceptor sites that result in an
in-frame deletion of 33 amino acids of the hCB1 receptor ami-
no terminus. This distinguishes it from the previously identi-
ﬁed hCB1a variant that uses diﬀerent splice donor and
acceptor sites and generated an altered amino terminal amino
acid sequence [15,18].
Given the low abundance of the cDNAs for both splice vari-
ants, it could be argued that they do not contribute to the can-
nabinoid pharmacology in diﬀerent tissues. In addition, it is
not possible to distinguish the hCB1b receptor protein from
that of the hCB1 receptor protein (hCB1b possessing no un-
ique epitope) in normal tissues. It remains therefore to be seen
what is the relative distribution at the cellular level and what
function the hCB1b receptor may have. It may be that hCB1b
is expressed in a small number of discrete cells where it plays a
role distinct to hCB1, or the amino terminus of the hCB1 alters
the eﬃciency by which mature receptor protein is produced.
Deletions in the amino terminus of hCB1 have been reported
resulting in improved delivery of functional receptor through
the protein maturation machinery of BHK cells [18]. These
deletions, whilst not being the same as the deletion encoded
264 E. Ryberg et al. / FEBS Letters 579 (2005) 259–264by the hCB1b receptor, are similar enough to suggest that
although the mRNA content for the hCB1b variant may be
low in tissues, it may result in more eﬃcient production of
functional receptors at the cell surface in some cell types.
The hCB1b splice variant that we have identiﬁed as well as the
hCB1a demonstrate signiﬁcantly altered ligand use as com-
pared to the hCB1 receptor. None of the known endogenous li-
gands of the hCB1 receptor identiﬁed to date have any
signiﬁcant agonist activity at either of the splice variants (Table
2), however, this does not exclude the possibility that additional
endocannabinoid ligands remain unidentiﬁed that may have
activity at hCB1b. The current lack of endogenous agonists
may be taken to indicate that these receptor forms are without
function and therefore are not of relevance in vivo. A number of
groups have described the intrinsic activity of hCB1 receptors
both in situ and in vitro [19]. The ﬁnding that 2-AG functions
as an inverse agonist at a potency similar to its agonist activity
at hCB1 may be taken as suggesting a reciprocal role versus
hCB1 for this ligand at either or both of the two splice variants
(Fig. 2(b) and (c)). It has previously been reported [20] that
anandamide showed no functional diﬀerence between hCB1
and hCB1a. However, it should be noted that in that study,
activity at the hCB1a was only observed at the top concentra-
tion of 1 lM. Activity starting at 1 lM is not inconsistent with
our ﬁndings of an EC50 of 11 lM for anandamide at the CB1a.
The novel receptor splice variant of the hCB1 receptor that
we call hCB1b and describe herein has an altered pharmacol-
ogy that is most apparent for the endogenous receptor ligands,
suggesting signiﬁcance for this alternative receptor form. Fur-
thermore, it appears to be most abundantly expressed in foetal
brain although it is detected in a number of tissues where hCB1
is also detected. In the absence of hCB1b speciﬁc ligands or
antibodies, it remains to be clariﬁed what functional role this
receptor form may have.
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